Stock Events

Stock Events

CanBas 

¥801
4
-¥6-0.74% 04:39 Today

Statistics

Day High
810
Day Low
770
52W High
1,317
52W Low
506
Volume
197,900
Avg. Volume
250,403
Mkt Cap
15.79B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-21.63
-18.05
-14.47
-10.89
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-1.97BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4575.TSE. It's not an investment recommendation.
Nippon Yusen Kabushiki Kaisha
3
9101.TSE
Bitcoin
2
BTC.CRYPTO
Mitsubishi UFJ Financial Group
2
8306.TSE
Japan Tobacco
2
2914.TSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Eisai
4523.TSE
Mkt Cap1.69T
Eisai Co., Ltd. - Competes in the oncology and neurology sectors, similar to CanBas' focus on cancer treatments.
Shionogi &.
4507.TSE
Mkt Cap2.12T
Shionogi & Co., Ltd. - Engages in the research, development, manufacturing, and marketing of pharmaceuticals, including cancer treatments.
Astellas Pharma
4503.TSE
Mkt Cap3.68T
Astellas Pharma Inc. - A competitor in the development of innovative cancer therapies.
Chugai Pharmaceutical
4519.TSE
Mkt Cap6.03T
Chugai Pharmaceutical Co., Ltd. - Specializes in biopharmaceuticals, including oncology, competing directly with CanBas' cancer research.
Daiichi Sankyo.
4568.TSE
Mkt Cap8.21T
Daiichi Sankyo Company, Limited - Focuses on pharmaceutical development, including oncology, which overlaps with CanBas' interests.
Kyowa Kirin.
4151.TSE
Mkt Cap1.75T
Kyowa Kirin Co., Ltd. - Competes in the field of pharmaceuticals with a strong focus on oncology and specialty medicines.
OtsukaLtd.
4578.TSE
Mkt Cap2.43T
Otsuka Holdings Co., Ltd. - Through its pharmaceutical segment, it competes in various therapeutic areas, including cancer.
Takeda Pharmaceutical
4502.TSE
Mkt Cap6.05T
Takeda Pharmaceutical Company Limited - A major player in the pharmaceutical industry with a significant focus on oncology, competing with CanBas.
Sumitomo Pharma.
4506.TSE
Mkt Cap419.94B
Sumitomo Pharma Co., Ltd. - Engages in the business of manufacturing, selling, and importing and exporting pharmaceuticals, including cancer treatments.
Nippon Shinyaku.
4516.TSE
Mkt Cap517.95B
Nippon Shinyaku Co., Ltd. - Focuses on the discovery, development, and marketing of pharmaceuticals, including oncology, directly competing with CanBas.

About

CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.
Show more...
CEO
Takumi Kawabe
Employees
14
Country
Japan
ISIN
JP3244570002

Listings

TSE
JP
4575.TSE

0 Comments

Share your thoughts

FAQ

What is CanBas stock price today?▼
The current price of 4575.TSE is ¥801 JPY — it has decreased by -0.74% in the past 24 hours. Watch CanBas stock price performance more closely on the chart.
What is CanBas stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Tokyo Stock Exchange exchange CanBas stocks are traded under the ticker 4575.TSE.
Is CanBas stock price growing?▼
4575.TSE stock has fallen by -9.5% compared to the previous week, the month change is a +8.25% rise, over the last year CanBas has showed a -33.11% decrease.
What is CanBas market cap?▼
Today CanBas has the market capitalization of 15.79B
When is the next CanBas earnings date?▼
CanBas is going to release the next earnings report on November 06, 2026.
What were CanBas earnings last quarter?▼
4575.TSE earnings for the last quarter are -21.63 JPY per share, whereas the estimation was N/A JPY resulting in a N/A surprise. The estimated earnings for the next quarter are N/A JPY per share.
What is CanBas revenue for the last year?▼
CanBas revenue for the last year amounts to 0 JPY.
What is CanBas net income for the last year?▼
4575.TSE net income for the last year is -1.97B JPY.
How many employees does CanBas have?▼
As of September 04, 2026, the company has 14 employees.
In which sector is CanBas located?▼
CanBas operates in the Health & Wellness sector.
When did CanBas complete a stock split?▼
CanBas has not had any recent stock splits.
Where is CanBas headquartered?▼
CanBas is headquartered in Numazu, Japan.